Kjølbæk Louise, Benítez-Páez Alfonso, Gómez Del Pulgar Eva M, Brahe Lena K, Liebisch Gerhard, Matysik Silke, Rampelli Simone, Vermeiren Joan, Brigidi Patrizia, Larsen Lesli H, Astrup Arne, Sanz Yolanda
Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958 Frederiksberg C, Denmark.
Microbial Ecology, Nutrition & Health Research Unit, Institute of Agrochemistry and Food Technology, Spanish National Research Council (IATA-CSIC), 46980, Paterna, Valencia, Spain.
Clin Nutr. 2020 Jan;39(1):67-79. doi: 10.1016/j.clnu.2019.01.012. Epub 2019 Feb 19.
BACKGROUND & AIMS: Gut microbiota composition is linked to obesity and metabolic syndrome. The nutrients and doses required to modulate the gut microbiota towards beneficially influence components of the metabolic syndrome are unclear. This study aimed to investigate diet-induced effects on the gut microbiota and metabolic markers in overweight individuals with indices of the metabolic syndrome.
A twelve-week randomized cross-over trial was conducted with two intervention periods separated by a washout period. The dietary intakes of interest were wheat bran extract, rich in arabinoxylan oligosaccharides (AXOS) (10.4 g/d AXOS) and polyunsaturated fatty acids (PUFA) (3.6 g/d n-3 PUFA). Dietary records, fecal and blood samples, as well as anthropometric data, were collected before and after intervention. Anthropometry and gastrointestinal symptoms were evaluated weekly. Gut microbiota composition was analyzed by massive sequencing of 16S ribosomal RNA gene V3V4 amplicons.
Twenty-seven participants completed the study (90%). Intake of AXOS induced an expected bifidogenic effect on gut microbiota (p < 0.01) and increased butyrate-producing bacterial species as well (p < 0.05). Beta-diversity analysis indicated that the structure of the gut microbiota only changed as a result of the AXOS intervention (Permanova = 1.90, p < 0.02) and no changes in metabolic markers were observed after any of the interventions.
AXOS intake has a bifidogenic effect and also increases butyrate producers in the gut microbiota; even though this type of dietary fiber did not modulate lipid or glucose metabolic parameters related to metabolic syndrome. Four-week PUFA intake did not induce any notable effect on the gut microbiota composition or metabolic risk markers.
Registered under ClinicalTrials.gov Identifier no. NCT02215343.
Registered at https://www.clinicaltrials.gov/ (NCT02215343).
H-4-2014-052.
2013-54-0522.
肠道微生物群组成与肥胖和代谢综合征相关。调节肠道微生物群以有益影响代谢综合征各组分所需的营养素和剂量尚不清楚。本研究旨在调查饮食对患有代谢综合征指标的超重个体的肠道微生物群和代谢标志物的影响。
进行了一项为期12周的随机交叉试验，有两个干预期，中间间隔一个洗脱期。感兴趣的饮食摄入量为富含阿拉伯木聚糖寡糖（AXOS）（10.4克/天AXOS）和多不饱和脂肪酸（PUFA）（3.6克/天n-3 PUFA）的麦麸提取物。在干预前后收集饮食记录、粪便和血液样本以及人体测量数据。每周评估人体测量和胃肠道症状。通过对16S核糖体RNA基因V3V4扩增子进行大规模测序分析肠道微生物群组成。
27名参与者完成了研究（90%）。AXOS的摄入对肠道微生物群产生了预期的双歧杆菌生成效应（p<0.01），并增加了产丁酸的细菌种类（p<0.05）。β-多样性分析表明，肠道微生物群的结构仅因AXOS干预而改变（置换多元方差分析=1.90，p<0.02），并且在任何干预后均未观察到代谢标志物的变化。
摄入AXOS具有双歧杆菌生成效应，还会增加肠道微生物群中产丁酸的细菌；尽管这种膳食纤维并未调节与代谢综合征相关的脂质或葡萄糖代谢参数。四周的PUFA摄入对肠道微生物群组成或代谢风险标志物未产生任何显著影响。
在ClinicalTrials.gov标识符编号NCT02215343下注册。
在https://www.clinicaltrials.gov/（NCT02215343）注册。
H-4-2014-052。
2013-54-0522。
